Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment
✍ Scribed by Józefa Węsierska-Gądek; Andreea Borza; Eva Walzi; Vladimir Krystof; Margarita Maurer; Oxana Komina; Stefanie Wandl
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 908 KB
- Volume
- 106
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Exposure of asynchronously growing human HeLa cervical carcinoma cells to roscovitine (ROSC), a selective cyclin‐dependent kinases (CDKs) inhibitor, arrests their progression at the transition between G~2~/M and/or induces apoptosis. The outcome depends on the ROSC concentration. At higher dose ROSC represses HPV‐encoded E7 oncoprotein and initiates caspase‐dependent apoptosis. Inhibition of the site‐specific phosphorylation of survivin and Bad, occurring at high‐dose ROSC treatment, precedes the onset of apoptosis and seems to be a prerequisite for cell death. Considering the fact that in HeLa cells the G~1~/S restriction checkpoint is abolished by E7, we addressed the question whether the inhibition of CDKs by pharmacological inhibitors in synchronized cells would be able to block the cell‐cycle in G~1~ phase. For this purpose, we attempted to synchronize cells by serum withdrawal or by blocking of the mitotic apparatus using nocodazole. Unlike human MCF‐7 cells, HeLa cells do not undergo G~1~ block after serum starvation, but respond with a slight increase of the ratio of G~1~ population. Exposure of G~1~‐enriched HeLa cells to ROSC after re‐feeding does not block their cell‐cycle progression at G~1~‐phase, but increases the ratio of S‐ and G~2~‐phase, thereby mimicking the effect on asynchronously growing cells. A quite different impact is observed after treatment of HeLa cells released from mitotic block. ROSC prevents their cell cycle progression and cells transiently accumulate in G~1~‐phase. These results show that inhibition of CDKs by ROSC in cells lacking the G~1~/S restriction checkpoint has different outcomes depending on the cell‐cycle status prior to the onset of treatment. J. Cell. Biochem. 106: 937–955, 2009. © 2009 Wiley‐Liss, Inc.